Loading...
•
Dec 31, 2019
Marinus Pharmaceuticals Q4 2019 Earnings Report
Reported financial results and provided a business update on clinical development activities.
Key Takeaways
Marinus Pharmaceuticals reported its financial results for the year ended December 31, 2019, with a net loss of $54.1 million. The company's cash and cash equivalents were $90.9 million as of December 31, 2019, expected to fund operations into the third quarter of 2021.
Cash and cash equivalents totaled $90.9 million as of December 31, 2019.
Research and development expenses increased to $43.0 million for the year ended December 31, 2019.
General and administrative expenses were $11.5 million for the year ended December 31, 2019.
The company reported a net loss of $54.1 million for the year ended December 31, 2019.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...